Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Breast Cancer Incidence Higher in Schizophrenia

JAMA Psychiatry; ePub 2018 Mar 7; Zhuo, et al

The incidence of breast cancer in women with schizophrenia is higher than that of the general female population, according to a recent study. However, significant heterogeneity exists among the included studies. This indicates that women with schizophrenia deserve intensive prevention and treatment of breast cancer. A literature search was conducted using the terms schizophrenia, schizophrenic, psychosis, combined with breast and cancer, tumor, neoplasm, or carcinoma. The final literature search was performed on August 15, 2017. 12 cohorts including 125,760 women were included in this meta-analysis. Researchers found:

  • Schizophrenia was associated with a significantly increased risk of breast cancer incidence in women (significantly increased risk, 1.31), with significant heterogeneity (I2 = 89%).
  • Substantial between-study variance was also suggested by the wide prediction interval (0.81-2.10).
  • The subgroup analysis results showed that the association was not significantly affected by whether breast cancer cases were excluded at baseline or the sample size of the included studies.

Zhuo C, Triplett PT. Association of schizophrenia with the risk of breast cancer incidence. A meta-analysis. [Published online ahead of print March 7, 2018]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2017.4748.

This Week's Must Reads

Depression May Be Linked with SLE Risk in Women, JAMA Psychiatry; ePub 2018 Sep 12; Roberts, et al

Women with MDD During the Childbearing Years, Depress Anxiety; ePub 2018 Sep 7; Freeman, et al

Resilience Examined in Older Adults with Depression, Am J Geriatr Psychiatry; ePub 2018 Aug 25; Laird, et al

Disparities in Depression Care Among Arab Americans, Depress Anxiety; ePub 2018 Aug 12; Dallo, et al

Telehealth vs In-Person Care for Depressed Veterans, J Clin Psychiatry; 2018 Aug 28; Egede, et al

Must Reads in Schizophrenia & Other Psychotic Disorders

FDA Approves Perseris for Schizophrenia, FDA news release; 2018 Jul 27

Gender Differences in Schizophrenia May Vary by Age, Am J Geriatr Psychiatry; ePub 2018 Jul 27; Muralidharan, et al

Folic Acid Exposure Linked with Psychosis Reduction, JAMA Psychiatry; ePub 2018 Jul 3; Eryilmaz, et al

FDA Approves New Dosing Formulation for Nuplazid, Acadia Pharmaceuticals Inc. news release; 2018 Jun 29

FDA Approves Initiation Drug for Schizophrenia, Alkermes plc news release; 2018 Jul 2